Answers are grounded in this paper and cite their sources.
Caution is advised when considering fondaparinux as an alternative to VKA in patients with multiple thrombotic risk factors, such as atrial fibrillation and bioprosthetic valves.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gian Marco Rosa (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: